Primary Transscleral Diode Laser Cyclophotocoagulation for Management of Glaucoma in Nanophthalmic Eyes

Abstract

Purpose: To assess the efficacy and safety of double-row trans-scleral cyclophotocoagulation in controlling intraocular pressure in patients with secondary angle closure glaucoma due to nanophthalmos, not being controlled by medical therapy. Methods: A prospective case series study that included 13 eyes of 8 patients diagnosed with secondary angle closure glaucoma due to nanophthalmos at the Giza eye subspeciality center, treated by Twenty- four cyclodiode applications in a double-row technique. Success was defined as complete success by control of intraocular pressure below 21 mmHg without medication and qualified success in which control of pressure below 21 mmHg achieved with one or two medications. Results: The average reduction in intraocular pressure at three months was 57.3% +/-SD 20.14, and at six months 44.5% +/- SD 32, with an average eye drop intake of 1.3 drops +/- SD 0.8. There was a significant reduction of intraocular pressure at six months compared to the pre-procedure pressure (P value 0.01). Complete success achieved in 3 eyes, pressure controlled without any medication and Qualified success in 9 eyes. Conclusion: Trans-scleral cyclophotocoagulation is a safe and effective primary therapy for managing glaucoma in nanophthalmic eyes.